MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody
Pei-Jung Lee,Chien-Min Hung,Ai-Jen Yang,Cheng-Yu Hou,Hung-Wen Chou,Yi-Chung Chang,Wen-Cheng Chu,Wen-Yen Huang,Wen-Chih Kuo,Chia-Chun Yang,Kuo-I Lin,Kuo-Hsuan Hung,Li-Chun Chang,Kang-Yun Lee,Han-Pin Kuo,Kung-Ming Lu,Hsin-Chih Lai,Ming-Liang Kuo,Wan-Jiun Chen
DOI: https://doi.org/10.1080/19490976.2024.2380061
IF: 12.2
Gut Microbes
Abstract:Cancer immunotherapy has been regarded as a promising strategy for cancer therapy by blocking immune checkpoints and evoking immunity to fight cancer, but its efficacy seems to be heterogeneous among patients. Manipulating the gut microbiota is a potential strategy for enhancing the efficacy of immunotherapy. Here, we report that MS-20, also known as "Symbiota®", a postbiotic that comprises abundant microbial metabolites generated from a soybean-based medium fermented with multiple strains of probiotics and yeast, inhibited colon and lung cancer growth in combination with an anti-programmed cell death 1 (PD1) antibody in xenograft mouse models. Mechanistically, MS-20 remodeled the immunological tumor microenvironment by increasing effector CD8+ T cells and downregulating PD1 expression, which were mediated by the gut microbiota. Fecal microbiota transplantation (FMT) from mice receiving MS-20 treatment to recipient mice increased CD8+ T-cell infiltration into the tumor microenvironment and significantly improved antitumor activity when combined with anti-PD1 therapy. Notably, the abundance of Ruminococcus bromii, which increased following MS-20 treatment, was positively associated with a reduced tumor burden and CD8+ T-cell infiltration in vivo. Furthermore, an ex vivo study revealed that MS-20 could alter the composition of the microbiota in cancer patients, resulting in distinct metabolic pathways associated with favorable responses to immunotherapy. Overall, MS-20 could act as a promising adjuvant agent for enhancing the efficacy of immune checkpoint-mediated antitumor therapy.